Related Experiment Videos
Flow cytometric DNA analysis of interleukin-2 responsive renal cell carcinoma
L G Gomella1, H Ehya, S M Steinberg
1Department of Urology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107.
Abstract:
Adoptive immunotherapy using interleukin-2 (IL-2) based therapy can result in marked tumor regression in some patients with metastatic renal cell carcinoma. DNA flow cytometry has not been previously studied as a predictor of outcome of this therapy. Archival paraffin embedded tumors were studied in 23 IL-2 treated patients with metastatic renal cell carcinoma. Eleven patients were complete responders (CR) and 12 were nonresponders (NR). In the CR group, 4/11 (40%) were diploid and 7/11 (60%) were aneuploid. In the NR group, 9/12 (75%) were diploid and 3/12 (25%) were aneuploid. Although there was a trend that patients with an aneuploid DNA pattern were more likely to undergo a complete response, ploidy pattern alone was not significantly predictive of response (p2 = 0.10, Fischer's exact test). When combining ploidy pattern with other variables that were predictive for complete response, such as good performance status and a higher pretreatment weight, prediction of complete response was not improved by including ploidy. This preliminary report suggests that DNA ploidy does not appear to provide any additional information concerning responsiveness to IL-2 based immunotherapy beyond that obtained by performance status and pretreatment weight in this patient population.
Insights
DNA ploidy analysis in metastatic renal cell carcinoma (mRCC) patients receiving interleukin-2 (IL-2) immunotherapy showed a trend towards aneuploidy in complete responders. However, DNA ploidy alone or combined with other factors did not significantly predict treatment outcomes.
Area of Science:
- Oncology
- Immunotherapy
- Genetics
Background:
- Adoptive immunotherapy with interleukin-2 (IL-2) can induce tumor regression in metastatic renal cell carcinoma (mRCC).
- Predictive markers for IL-2 therapy response in mRCC are crucial for treatment optimization.
- The role of DNA ploidy as a prognostic factor in IL-2 treated mRCC remains uninvestigated.
Purpose of the Study:
- To investigate the utility of DNA flow cytometry and DNA ploidy patterns as predictors of treatment outcome in patients with mRCC receiving IL-2 based immunotherapy.
- To determine if DNA ploidy status adds prognostic value beyond established clinical factors.
Main Methods:
- Analysis of archival paraffin-embedded tumor samples from 23 mRCC patients treated with IL-2.
- DNA flow cytometry was performed to assess DNA ploidy (diploid vs. aneuploid).
- Correlation of ploidy patterns with clinical response (complete response vs. nonresponse) and other clinical variables (performance status, pretreatment weight).
Main Results:
- Among complete responders (CR), 60% had aneuploid DNA patterns, while 75% of nonresponders (NR) had diploid patterns.
- DNA ploidy pattern alone was not a statistically significant predictor of complete response (p=0.10).
- Incorporating DNA ploidy with performance status and pretreatment weight did not improve the prediction of complete response.
Conclusions:
- DNA ploidy status does not appear to provide significant additional prognostic information for IL-2 immunotherapy response in mRCC patients.
- Established clinical factors like performance status and pretreatment weight remain important predictors of treatment outcome.
- Further research may explore other genetic markers or combinations of factors for predicting IL-2 therapy response in mRCC.